AUTOLOGOUS MATRIX-INDUCED CHONDROGENESIS MARKET ANALYSIS

Market Challenges And Opportunities

Autologous Matrix-induced Chondrogenesis Market - Drivers

Increasing number of joint and bone disorders such as osteoporosis and arthritis globally is expected to drive the autologous matrix-induced chondrogenesis market growth during the forecast period. For instance, according to the National Center for Biotechnology Information (NCBI) 2016 report, over 200 million people are suffering from osteoporosis worldwide in 2015. 1 in 3 women over the age of 50 years and 1 in 5 men will experience osteoporosis fractures in their lifetime.

Rising number of surgeries is expected to drive the autologous matrix-induced chondrogenesis market growth during the forecast period. For instance, according to American Academy of Orthopaedic Surgeon (AAOS) 2019 report, around 267,000 knee replacements are performed each year in the U.S.

Autologous Matrix-induced Chondrogenesis Market - Restraints

Inefficient system of reimbursement and high cost of cartilage replacement are major factors restraining growth of the autologous matrix-induced chondrogenesis market. Several health insurance companies do not insure AMIC procedure. For instance, according to Blue Cross Blue Shield of North Carolina 2019, for patients without health insurance, a total hip replacement usually costs between US$ 31,839 and US$ 44,816, with an average cost of US$ 39,299 in the U.S.